Abstracts tagged "rheumatoid arthritis"

Abstract Number: 983 • 2019 ACR/ARP Annual Meeting
Fecal Transfer from Mice on High or Low Magnesium Diets Confers Arthritis Protection
Teresina Laragione¹, Carolyn Harris ¹ and Percio Gulko ¹, ¹Icahn School of Medicine at Mount Sinai, New York, NY
Background/Purpose: Magnesium (Mg) plays a key role in the immune response. We have previously demonstrated that alterations in the Mg balance by increasing or decreasing…
Abstract Number: 1385 • 2019 ACR/ARP Annual Meeting
Discontinuation of Oral Glucocorticoid After Initiation of Biological DMARDs Due to a Higher Dose of Methotrexate; A Retrospective Observational Study Based on Data from a Japanese Multicenter Registry Study
Mochihito Suzuki¹, Toshihisa Kojima ², Nobunori Takahashi ², Shuji Asai ² and Naoki Ishiguro ², ¹Nagoya University Graduate School of Medicine, Nagoya, Japan, ²Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan
Background/Purpose: In the treatment of rheumatoid arthritis (RA), glucocorticoid that provide anti-inflammatory effects is an important drug. We recommend discontinuing of glucocorticoid as soon as…
Abstract Number: 1999 • 2019 ACR/ARP Annual Meeting
NADPH Oxidase 4 Regulates the Migration and Invasion of Synoviocytes in Rheumatoid Arthritis Through Pro-angiogenic Factor Secretion
Ha-Reum Lee¹, Su-Jin Yoo ², Chan-Geol Park ², Jinhyun Kim ², In Seol Yoo ² and Seong Wook Kang ², ¹Chungnam National University Hospital,, Daejeon, Republic of Korea, ²Chungnam National University Hospital, Daejeon, Republic of Korea
Background/Purpose: Fibroblast-like synoviocytes (FLS) are key effector cells in the pathogenesis of rheumatoid arthritis (RA) through the increased cell migration, degradation of extracellular matrix, and…
Abstract Number: 2377 • 2019 ACR/ARP Annual Meeting
Methotrexate Discontinuation and Dose Decreases After Therapy with Tocilizumab: Results from the Corrona Rheumatoid Arthritis Registry
Dimitrios Pappas¹, Taylor Blachley ², Steve Zlotnick ³, Jennie Best ³, Kelechi Emeanuru ² and Joel Kremer ⁴, ¹Columbia University, New York, NY, ²Corrona, LLC, Waltham, MA, ³Genentech, Inc., South San Francisco, CA, ⁴Albany Medical College and The Center for Rheumatology; Corrona, LLC, Albany, NY
Background/Purpose: Methotrexate (MTX) is frequently prescribed with biologic disease-modifying antirheumatic drugs. Evidence has shown that tocilizumab (TCZ) monotherapy is effective in the treatment of patients…
Abstract Number: 495 • 2019 ACR/ARP Annual Meeting
Pre-Rheumatoid Arthritis Diagnosis Prevalence of Commercial CCP Antibody Positivity Increases over Time with Strong Agreement Between Commercial Assays and Positivity Is Predicative of Developing Rheumatoid Arthritis Within 3 Years
Steven Taylor¹, Mark Parish ², LauraKay Moss ³, Marie Feser ⁴, Elizabeth Mewshaw ⁵, Jess Edison ⁵ and Kevin Deane ⁴, ¹University of Colorado - Denver, Denver, CO, ²University of Colorado Denver, Aurora, CO, ³University of Colorado Denver, Division of Rheumatology, Aurora, CO USA, Aurora, CO, ⁴University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA, Aurora, CO, ⁵Walter Reed National Military Medical Center, Bethesda, MD
Background/Purpose: Rheumatoid arthritis (RA) related autoantibodies, in particular antibodies to citrullinated proteins (ACPA), predict likelihood of developing future RA. Indeed, clinical trials for RA prevention…
Abstract Number: 531 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of Gonadotropin-Releasing Hormone Antagonism in Severe Biologic Refractory Rheumatoid Arthritis
Anita Kass¹, Hans Christian Gulseth ¹ and Camilla Zettel ¹, ¹Betanien Hospital, Skien, Norway
Background/Purpose: The pathogenesis of rheumatoid arthritis (RA) is unclear, and additional therapeutic approaches are needed. The improvement of RA disease activity during pregnancy, and flares during the…
Abstract Number: 985 • 2019 ACR/ARP Annual Meeting
Inhibition of Calcium/calmodulin-dependent Protein Kinase IV in Rheumatoid Arthritis: Dual Effect on Th17 Cell Activation and Osteoclastogenesis
Tomohiro Koga¹, Tomohito Sato ², Yushiro Endo ¹, Sosuke Tsuji ¹, Ayuko Takatani ¹, Toshimasa Shimizu ¹, Remi Sumiyoshi ¹, Takashi Igawa ¹, Shin-ya Kawashiri ¹, Naoki Iwamoto ¹, Kunihiro Ichinose ¹, Mami Tamai ¹, Hideki Nakamura ¹, Tomoki Origuchi ³, Nobuya Yoshida ⁴, Masataka Umeda ⁵, George Tsokos ⁴ and Atsushi Kawakami ⁶, ¹Nagasaki University Graduate School of Biomedical Sciences, Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki, Japan, ²Nagasaki University, Nagasaki, Japan, ³Nagasaki University School of health sciences, Division of physical therapy, Nagasaki, Japan, ⁴Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ⁵Beth Israel Deaconess Medical Center, Boston, MA, ⁶Nagasaki University Graduate School of Biomedical Sciences, Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki
Background/Purpose: Background: CD4 + T cells are important in the pathogenesis of rheumatoid arthritis (RA), and therapies targeting the differentiation of osteoclasts are attracting attention. Calcium/calmodulin-dependent…
Abstract Number: 1400 • 2019 ACR/ARP Annual Meeting
Real Life Retention of Tofacitinib in Patients with Rheumatoid Arthritis
Aniela Croiteru ¹, Merav Lidar ², Tatiana Reitblat³, Devy Zisman ⁴, Alexandra Balbir-Gurman ⁵, Tanya Meshiach ⁵, Ronit Almog ⁵ and Ori Elkayam ⁶, ¹Tel Aviv medical center, Tel Aviv, Israel, ²Sheba Medical Center, Ramat Gan, Israel, ³Barzilai Medical Center, Ashkelon, Israel, ⁴Carmel Hospital and Ruth and Bruce Rappaport Faculty of Medicine, Technion, Israel, Haifa, Israel, ⁵Rambam Medical Center, Haifa, Israel, ⁶Rheumatology Department, Tel Aviv Medical Center, and Sackler Faculty of Medicine, Tel Aviv University, Israel., Tel Aviv, Israel
Background/Purpose: Tofacitinib (Xeljanz) is an approved treatment for Rheumatoid Arthritis (RA) but data on its use in “real life” are limited. We sought to analyze…
Abstract Number: 2002 • 2019 ACR/ARP Annual Meeting
Presence of the MerTK Receptor on Human Synovial Tissue Macrophages Lowers Inflammatory Cytokine Production and Activation of the MerTK+CD206+ Subpopulation Limits the Inflammatory Response of Synovial Fibroblasts
Samuel Finlay¹, Stefano Alivernini ², Aziza Elmesmari ³, Barbara Tolusso ², Luca Petricca ², Clara Di Mario ⁴, Annunziata Capacci ², Andrew Filer ⁵, Gianfranco Ferraccioli ², Iain McInnes ¹, Elisa Gremese ² and Mariola Kurowska-Stolarska ¹, ¹Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, United Kingdom, ²Division of Rheumatology - Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, ³Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, Scotland, United Kingdom, ⁴Institute of Rheumatology - Università Cattolica del Sacro Cuore, Rome, Italy, ⁵Institute of Inflammation and Ageing College of Medical and Dental Sciences University of Birmingham, Birmingham, United Kingdom
Background/Purpose: Background: A substantial proportion of Rheumatoid Arthritis patients do not respond to treatment and only a small proportion achieve sustained disease remission. We showed…
Abstract Number: 2380 • 2019 ACR/ARP Annual Meeting
Improving Depression by Joint Surgery in Established Rheumatoid Arthritis; Results from Multicenter Prospective Cohort Study for Evaluation of Joint Surgery on Patient’s Reported Outcome
Toshihisa Kojima¹, Masayo Kojima ², Hajime Ishikawa ³, Sakae Tanaka ⁴, Nobuhiko Haga ⁵, Keiichiro Nishida ⁶, Masao Yukioka ⁷, Jun Hashimoto ⁸, Hisaaki Miyahara ⁹, Yasuo Niki ¹⁰, Tomoatsu Kimura ¹¹, Hiromi Oda ¹², Shuji Asai ¹, Koji Funahashi ¹³ and Naoki Ishiguro ¹, ¹Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan, ²Nagoya City University Graduate School of Medicne, Nagoya, Japan, ³Niigata Rheumatic Center, Niigata, Japan, ⁴University of Tokyo, Tokyo, Japan, ⁵The University of Tokyo Hospital, Tokyo, Japan, ⁶Okayama University, Graduate School of Medicine, Okayama, Japan, ⁷Yukioka Hospital, Osaka, Japan, ⁸National Hospital Organization Osaka Minami Medical Center, Kawachinagano, Japan, ⁹National Hospital Organization, Kyushu Medical Center, Fukuoka, Japan, ¹⁰Keio University, School of Medicine, Tokyo, Japan, ¹¹University of Toyama, Faculty of Medicine, Toyama, Japan, ¹²Department of Orthopedic Surgery, Faculty of Medicine, Saitama Medical University, Saitama, Japan, ¹³Kariya-Toyota General Hosptal, Kariya, Japan
Background/Purpose: Total management including reconstructive joint surgery and rehabilitation should be needed for further improvements of physical function for long-standing RA patients. In these days,…
Abstract Number: 520 • 2018 ACR/ARHP Annual Meeting
Factors Associated with the Developement of Severe Respiratory Infections in Patients with Rheumatoid Arthritis Included in a Vaccination Program
Lucia C. Domínguez-Casas¹, Paz Rodríguez-Cundín², Vanesa Calvo-Río³, Nuria Vegas-Revenga³, Virginia Portilla⁴, F. Antolin², M. Rebollo-Rodrigo², Alfonso Corrales¹, Diana Prieto Peña³, Monica Calderón Goercke³, Miguel Angel González-Gay¹ and Ricardo Blanco¹, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ²Preventive Medicine, Preventive Medicine. Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain., Santander, Spain, ³Rheumatology, Rheumatology. Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ⁴Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain
Background/Purpose: Rheumatoid arthritis(RA) patients are at increased risk of infections particularly respiratory infections. These may be augmented due to RA itself and to immunosuppressive durgs,…
Abstract Number: 2047 • 2018 ACR/ARHP Annual Meeting
Synovial Fluid Cytokines /Chemokines and Proteins from the Knees of Symptomatic RA and OA Patients Which Correlate with the Magnitude of the Inflammatory Response As Measured By Synovial Fluid WBC Levels
Richard Meehan¹, Eric Hoffman², Mary Wolf³, Elizabeth Regan⁴, Prashant Parmar⁵, Karin Pacheco⁶, Jim Crooks⁷ and Vijaya Knight⁸, ¹MEDICINE, National Jewish Health, Denver, CO, ²Medicine/Rheumatology, National Jewish Health, Denver, CO, ³Pathology Department, National Jewish Health, Denver, CO, ⁴Medicine, National Jewish Health, Denver, CO, ⁵Internal Medicine, St Joseph Hospital, Denver, CO, ⁶MEDICINE/ Occupational Medince, National Jewish Health, Denver, CO, ⁷Biostatistics, National Jewish Health, Denver, CO, ⁸Pathology, ADX laboratory, National Jewish Health, Denver, CO
Background/Purpose: Synovial fluid (SF) provides nutritional support for cartilage and contains numerous catabolic and anabolic cytokines, chemokines and proteins. The precise role of these proteins…
Abstract Number: 552 • 2018 ACR/ARHP Annual Meeting
Drug Tolerability and Discontinuation Reasons of 7 Biologics in 4466 Treatment Courses of Rheumatoid Arthritis -the Answer Cohort Study-
Kosuke Ebina¹, Makoto Hirao², Motomu Hashimoto³, Wataru Yamamoto⁴, Akira Onishi⁵, Toru Hirano⁶, Ryota Hara⁷, Masaki Katayama⁸, Shuzo Yoshida⁹, Koji Nagai⁹, Yonsu Son¹⁰, Hideki Amuro¹⁰, Kengo Akashi¹¹, Koichi Murata³, Kosaku Murakami¹², Keiichi Yamamoto¹³ and Hideki Yoshikawa¹⁴, ¹Orthopaedic Surgery, Osaka University Graduate School of Medicine, Suita, Japan, ²Orthopaedic Surgery, Osaka University, Graduate School of Medicine, Suita, Japan, ³Department of Advanced Medicine for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁴Department of Health Information Management, Kurashiki Sweet Hospital, Okayama, Japan, ⁵Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ⁶Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine, Suita, Japan, ⁷The Center for Rheumatic Diseases, Department of Orthopaedic Surgery, Nara Medical University, Kashihara, Japan, ⁸Department of Rheumatology, Osaka Red Cross Hospital, Osaka, Japan, ⁹Department of Internal Medicine (IV), Osaka Medical College, Osaka, Japan, ¹⁰First Department of Internal Medicine, Kansai Medical University, Osaka, Japan, ¹¹Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ¹²Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ¹³Department of Medical Statistics, Osaka City University, Osaka, Japan, ¹⁴Department of Orthopedic Surgery, Osaka University Graduate School of Medicine, Suita Osaka, Japan
Background/Purpose: Drug tolerability indicates both the patient’s and doctor’s satisfaction and useful summary measure of overall treatment effectiveness and toxicity. Although more than 5 years…
Abstract Number: 2353 • 2018 ACR/ARHP Annual Meeting
Attitudes and Beliefs Regarding Methotrexate in Patients with Rheumatoid Arthritis: Results from Australian Rheumatology Association Database
Nieves Leonardo^1,2, Susan Lester^3,4, Michelle Graham⁵, Samuel Whittle^1,6, Debra Rowett^7,8, Rachelle Buchbinder^9,10 and Catherine Hill^6,11,12, ¹Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide, Australia, ²Rheumatology, The Queen Elizabeth Hospital, Adelaide, Australia, ³Rheumatology Unit, The Queen Elizabeth Hospital, Adelaide, Australia, ⁴Discipline of Medicine, Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide, Australia, ⁵Arthritis Queensland, Queensland, Australia, ⁶The Queen Elizabeth Hospital, Adelaide, Australia, ⁷School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, Australia, ⁸Drug and Therapeutics Information Service, Southern Adelaide Local Health Network, Adelaide, Australia, ⁹Cabrini Institute, Victoria, Australia, ¹⁰Monash University, Melbourne, Australia, ¹¹Rheumatology Unit, Royal Adelaide Hospital, Adelaide, Australia, ¹²Medicine, The University of Adelaide, Adelaide, Australia
Background/Purpose: To determine beliefs about methotrexate (MTX) in patients with Rheumatoid Arthritis (RA) in relation to views obtained from a range of information sources.Methods: RA…
Abstract Number: 593 • 2018 ACR/ARHP Annual Meeting
Predictors of Persistence of Biologic Drug Step-Down Strategies in Inflammatory Arthritis: An Observational Study in Clinical Practice up to Seven Years of Follow-up
Sebastian C Rodriguez-Garcia¹, Raul Castellanos-Moreira Sr.¹, José Inciarte-Mundo², M. Victoria Hernández³, Virginia Ruiz-Esquide², Andrea Cuervo¹, Julio Ramírez², Juan Cañete¹, Jose Gomez Puerta¹ and Raimon Sanmartí¹, ¹Rheumatology Service, Hospital Clínic de Barcelona, Barcelona, Spain, ²Rheumatology, Hospital Clínic de Barcelona, Barcelona, Spain, ³Rheumatology, Hospital Clinic. Barcelona. Spain, Barcelona, Spain
Background/Purpose: Recommendations and guidelines for the management of Rheumatoid Arthritis (RA) and spondyloarthritis (SpA) with bDMARD include dose-tapering as an adequate option for patients on…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].